- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01207596
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain: An Open Label Study
Study Overview
Detailed Description
Neuropathic pain state is usually refractory to most analgesic regimens and requires polypharmacy for symptomatic relief. Current treatment options for neuropathic pain include both oral and topical medications. Most commonly prescribed oral treatments include antidepressants (eg, amitriptyline, desipramine, and duloxetine), antiepileptics (eg, gabapentin, pregabalin), and opiates such as tramadol and morphine. Current topical treatments include the lidocaine patch and the capsaicin patch. Many patients have inadequate pain relief in spite of these treatment options.
Currently, there are no treatments available for treatment of neuropathy itself other than treating the underlying cause and addressing the symptomatic relief for pain. Current drug therapies for neuropathic pain provide inadequate pain relief and undesirable side effects including sedation and cognitive dysfunction. It is not uncommon to use a combination of agents for the treatment of neuropathic pain to minimize the side effects. Although treating the mild to moderate pain may be relatively easy, it is very challenging for severe neuropathic pain. Although the use of opiates for neuropathic pain is well accepted, it remains controversial because of the potential for abuse and diversion.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kansas
-
Leawood, Kansas, United States, 66211
- International Clinical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- individuals with chronic pain of more than 6 months duration
- pain is determined to be secondary to a documented neuropathy
- patients who are tolerant of opiates (60 mg of morphine or equivalent for at least one week)
- male or female patients aged 18-75 yrs and have signed a written informed consent form and privacy statement
- female patients of child-bearing potential must be using an acceptable form of birth control
Exclusion Criteria:
- pregnant or lactating women
- allergy to morphine or its derivatives
- history of alcohol or substance abuse in the last 3 yrs
- participation in any other clinical trial in the last 30 days
- uncontrolled pain
- patient who is deemed to be medically unstable by principal investigator
- history of severe lung disease or asthma that is deemed medically significant by principal investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Hydromorphone
|
Oral hydromorphone extended release, once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Average Pain Over the Last 24 Hrs on the Brief Pain Inventory (BPI) Scale
Time Frame: Baseline visit to Week 12 or last visit
|
The primary efficacy measure was the change from baseline to end of study on question #5 ("average pain") of the Brief Pain Inventory (BPI): "Please rate your pain by marking the box beside the number that best describes your pain on the average," where 0 = no pain and 10 = pain as bad as you can imagine.
|
Baseline visit to Week 12 or last visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Average Pain Over the Last 24 Hrs on the Brief Pain Inventory (BPI) Scale Question #3: the Number That Best Describes Your Pain at Its Worst in the Last 24 Hours
Time Frame: Baseline visit to Week 12 or last visit
|
Change from baseline to end of study on question #3 ("worst pain") of the Brief Pain Inventory (BPI): "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours," where 0 = no pain and 10 = pain as bad as you can imagine.
|
Baseline visit to Week 12 or last visit
|
Change From Baseline in the Average Pain Over the Last 24 Hrs on the Brief Pain Inventory (BPI) Scale Question #4: the Number That Best Describes Your Pain at Its Least in the Last 24 Hours
Time Frame: Baseline visit to Week 12 or last visit
|
Change from baseline to end of study on question #4 ("least pain") of the Brief Pain Inventory (BPI): "Please rate your pain by marking the box beside the number that best describes your pain at its least in the last 24 hours," where 0 = no pain and 10 = pain as bad as you can imagine.
|
Baseline visit to Week 12 or last visit
|
Change From Baseline in the Average Pain Over the Last 24 Hrs on the Brief Pain Inventory (BPI) Scale Question #6: the Number That Tells How Much Pain You Have Right Now
Time Frame: Baseline visit to Week 12 or last visit
|
Change from baseline to end of study on question #4 ("current pain") of the Brief Pain Inventory (BPI): "Please rate your pain by marking the box beside the number that tells how much pain you have right now," where 0 = no pain and 10 = pain as bad as you can imagine.
|
Baseline visit to Week 12 or last visit
|
Sleep Quality Assessment (SQA)
Time Frame: Baseline visit to Week 12 or last visit
|
Sleep Quality Assessment (SQA) scale, asking patients to assess the degree that pain has interfered with their sleep in the last 24 hours (where 0 = does not interfere and 10 = completely interferes)
|
Baseline visit to Week 12 or last visit
|
Pain Quality Assessment Scale (PQAS)
Time Frame: Baseline visit to 12 weeks visit
|
The PQAS is a 20-item scale that quantifies the quality and intensity of neuropathic and non-neuropathic pain; scores range from 1 to 200, with higher scores indicating more severe pain
|
Baseline visit to 12 weeks visit
|
Global Assessment of Treatment Satisfaction
Time Frame: Baseline visit to Week 12 or last visit
|
Patients were asked to rate their global assessment of treatment satisfaction, ranging from "very dissatisfied" to "very satisfied".
Adverse events were monitored throughout the study
|
Baseline visit to Week 12 or last visit
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX-NP2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Hospices Civils de LyonCompletedPharmacoresistant Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
University Hospital, Clermont-FerrandCompletedNeuropathic Pain RebelFrance
-
University Hospital, Strasbourg, FranceTerminatedPostthoracotomy Pain | Postthoracoscopy Neuropathic PainFrance
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
Clinical Trials on Hydromorphone
-
Mayo ClinicRecruitingPain ControlUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Brigham and Women's HospitalTerminatedPain | Healthy | PregnancyUnited States
-
Thomas Jefferson UniversityCompleted
-
Shirley Ryan AbilityLabMallinckrodtCompletedLow Back PainUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Providence Healthcare; Innerchange...CompletedHeroin Dependence | Opioid DependenceCanada
-
Fujian Cancer HospitalCompleted
-
Dr. Anthony HoRecruitingPain Control After Elective HepatectomyCanada
-
Mundipharma Research GmbH & Co KGCompletedConstipationRomania, Switzerland, Israel, Belgium, Germany, Australia, Austria, Czech Republic, Denmark, Finland, France, Netherlands, Poland, United Kingdom
-
Hordinsky, Maria K., MDTerminated